Featured Industry Insights
Uncovering Real-World Patient Insights With Social Media and NLP
Historically, drug researchers have relied on methods such as focus groups and questionnaires for first-person accounts of patient-reported outcomes. Social media has emerged as a lower cost alternative that is increasingly accepted as a reputable source of information by the research community.
Raising the Bar in Proteomics
How do we continue to push the boundaries in analytical capabilities, increase confidence in results and apply MS to a wider range of research questions? Technology Networks posed these questions to Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, in a recent interview.
Latest Industry Insights
How Data Analytics Is Reducing Transfusion Use and Length of Hospital Stays
With the advent of electronic health records, it is now possible to access larger, more comprehensive volumes of medical statistics than ever before. In this Insight, Chris Patrick, CEO of cloud provider Nuvodia, explores how this could lead to a medical data revolution.
What Can We Learn From Animal and Plant Viruses?
Dr. Arvind Varsani discusses the work that the global scientific community has achieved through collaboration, especially in the pandemic.
DMT: A Trip To Get Away From Depression?
The revival of psychedelic medicine is well underway. We spoke with Small Pharma CEO Peter Rands to discuss the unique features of the psychedelic DMT and updates from the company’s latest trials.
Innovations in Single-Cell Proteomics Drive Advances in Disease Research
Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.
Agilent Science Futures – An Interview With Rajannya Sen
In this instalment of Science Futures, Rajannya discusses the real-world applications of her research and explains how technologies have steered her work.
Innovating Reversible Cell Therapies With RNA
In this interview, Murat Kalayoglu, president and CEO of Cartesian Therapeutics discusses the company’s efforts to develop RNA-modified cell therapies that expand past oncology.
A Path to Net Zero
Agilent recently announced its commitment to achieve net-zero greenhouse gas emissions no later than 2050. We spoke to them to learn how you go about making a global company with 16,300 employees a net-zero business.
How To Empower Ground-Breaking Research With Remote Compute Power
The University of Aberdeen’s HPC usage rocketed by 50% during the height of the pandemic. In this insight, Dean Phillips, assistant director, digital and information services at the University explains how pioneering research was able to continue remotely when moved off campus.
Agilent Science Futures – An Interview With Max Lennart Feuerstein
In this instalment of Science Futures, we hear from Max Lennart Feuerstein. Max tells us more about his research and how it could drive technical enhancements of data acquisition workflows
ASMS Introduces… An Overview of What’s New for 2021
Here we highlight some of the innovations featured at the 69th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics.